Evidence map›Paper›PMID 33172499›Full record

ArticleAlzheimer's research & therapy2020

Combination of snapshot hyperspectral retinal imaging and optical coherence tomography to identify Alzheimer's disease patients.

Sophie Lemmens, Toon Van Craenendonck, Jan Van Eijgen, Lies De Groef, Rose Bruffaerts, Danilo Andrade de Jesus, Wouter Charle, Murali Jayapala, Gordana Sunaric-Mégevand, Arnout Standaert and 7 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 4 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Ocular changes as potential biomarkers for early diagnosis of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Retina Phantom Model for Hyperspectral Imaging.Proceedings of SPIE--the International Society for Optical Engineering · 2025
    Article
  20. A Dual-Camera High-Resolution Hyperspectral Imaging System for the Retina.Proceedings of SPIE--the International Society for Optical Engineering · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 2 countries.

Sophie LemmensDepartment of Ophthalmology, University Hospitals UZ Leuven, Herestraat 49, 3000, Leuven, Belgium. sophie.1.lemmens@uzleuven.be.ORCID 0000-0002-6842-1747
Toon Van CraenendonckVITO (Flemish Institute for Technological Research), Health Unit, Boeretang 200, 2400, Mol, Belgium.
Jan Van EijgenDepartment of Ophthalmology, University Hospitals UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.
Lies De GroefNeural Circuit Development and Regeneration Research Group, Department of Biology, KU Leuven, Naamsestraat 61, 3000, Leuven, Belgium.
Rose BruffaertsLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Danilo Andrade de JesusDepartment of Neurosciences, Research Group Ophthalmology, KU Leuven, Biomedical Sciences Group, Herestraat 49, 3000, Leuven, Belgium.
Wouter CharleImec, Kapeldreef 75, 3001, Leuven, Belgium.
Murali JayapalaImec, Kapeldreef 75, 3001, Leuven, Belgium.
Gordana Sunaric-MégevandClinical Research Center, Mémorial A. de Rothschild, 22 Chemin Beau Soleil, 1208, Geneva, Switzerland.
Arnout StandaertVITO (Flemish Institute for Technological Research), Health Unit, Boeretang 200, 2400, Mol, Belgium.
Jan TheunisVITO (Flemish Institute for Technological Research), Health Unit, Boeretang 200, 2400, Mol, Belgium.
Karel Van KeerDepartment of Ophthalmology, University Hospitals UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.
Mathieu VandenbulckeDivision of Psychiatry, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Lieve MoonsNeural Circuit Development and Regeneration Research Group, Department of Biology, KU Leuven, Naamsestraat 61, 3000, Leuven, Belgium.
Rik VandenbergheLaboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.
Patrick De BoeverVITO (Flemish Institute for Technological Research), Health Unit, Boeretang 200, 2400, Mol, Belgium.
Ingeborg StalmansDepartment of Ophthalmology, University Hospitals UZ Leuven, Herestraat 49, 3000, Leuven, Belgium.
KU Leuven · BEUniversitair Ziekenhuis Leuven · BEFlemish Institute for Technological Research · BEIMEC · BEAllen Institute for Brain Science · USUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe eye offers potential for the diagnosis of Alzheimer's disease (AD) with retinal imaging techniques being explored to quantify amyloid accumulation and aspects of neurodegeneration. To assess these changes, this proof-of-concept study combined hyperspectral imaging and optical coherence tomography to build a classification model to differentiate between AD patients and controls.

methodsIn a memory clinic setting, patients with a diagnosis of clinically probable AD (n = 10) or biomarker-proven AD (n = 7) and controls (n = 22) underwent non-invasive retinal imaging with an easy-to-use hyperspectral snapshot camera that collects information from 16 spectral bands (460-620 nm, 10-nm bandwidth) in one capture. The individuals were also imaged using optical coherence tomography for assessing retinal nerve fiber layer thickness (RNFL). Dedicated image preprocessing analysis was followed by machine learning to discriminate between both groups.

resultsHyperspectral data and retinal nerve fiber layer thickness data were used in a linear discriminant classification model to discriminate between AD patients and controls. Nested leave-one-out cross-validation resulted in a fair accuracy, providing an area under the receiver operating characteristic curve of 0.74 (95% confidence interval [0.60-0.89]). Inner loop results showed that the inclusion of the RNFL features resulted in an improvement of the area under the receiver operating characteristic curve: for the most informative region assessed, the average area under the receiver operating characteristic curve was 0.70 (95% confidence interval [0.55, 0.86]) and 0.79 (95% confidence interval [0.65, 0.93]), respectively. The robust statistics used in this study reduces the risk of overfitting and partly compensates for the limited sample size.

conclusionsThis study in a memory-clinic-based cohort supports the potential of hyperspectral imaging and suggests an added value of combining retinal imaging modalities. Standardization and longitudinal data on fully amyloid-phenotyped cohorts are required to elucidate the relationship between retinal structure and cognitive function and to evaluate the robustness of the classification model.

Indexed as

Alzheimer DiseaseTomography, Optical CoherenceBiomarkersHumansRetinaROC CurveBiomarkersAlzheimer’s diseaseAmyloid-beta (Aβ)BiomarkerBrainCognitive impairmentHyperspectral imagingMachine learningNeurodegenerationRetina

Identifiers

PMID33172499
PMCPMC7654576
OpenAlexW3102798554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.